Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 16:26:9.
doi: 10.1186/s40709-019-0101-2. eCollection 2019 Dec.

The decreased SIRT1 level may account for the lipid profile in chronic kidney disease

Gang Chen  1 , Xuemei Li  1
Affiliations

The decreased SIRT1 level may account for the lipid profile in chronic kidney disease

Gang Chen et al. J Biol Res (Thessalon). .

Abstract

Dysregulated lipid profile with hypertriglyceridemia and increased low-density lipoprotein (LDL) is common in chronic kidney disease (CKD) whereas the reason is unclear. A similar phenomenon is found in the elder population. Silent information regulator-1 (SIRT1) associates with many modulators regulating lipid metabolism and results in increased expression of sterol regulatory element-binding proteins (SREBPs), which functions as a key modulator in lipid synthesis. Since CKD is being viewed as a premature aging model and SIRT1 is known to decrease during the process of aging, we hypothesize that SIRT1 level is reduced in the liver when CKD develops and eventually result in dysregulated lipid profile.

Keywords: Chronic kidney disease; Dyslipidemia; Silent information regulator-1; Sterol regulatory element-binding proteins.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
The key pathways and target genes of the SIRT1 concerning cholesterol, fatty acids, bile acid, and triglyceride homeostasis. Decreased SIRT1 eventually promotes triglyceride, fatty acid, and cholesterol synthesis, whereas represses fatty acid beta-oxidation. As a result, the lipid profiles alter due to the SIRT1 level
See this image and copyright information in PMC

References

    1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE. 2016;11:e0158765. - PMC - PubMed
    1. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384. - PubMed
    1. Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol. 2006;17:S226–S230. - PubMed
    1. Vaziri ND. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr. 2010;20:S35–S43. - PubMed
    1. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091. - PubMed

LinkOut - more resources